Karol

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4794551/publications.pdf

Version: 2024-02-01

		304602	330025
61	1,527	22	37
papers	citations	h-index	g-index
63	63	63	2978
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499.	0.9	195
2	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842.	0.9	148
3	Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity. European Urology, 2019, 75, 498-505.	0.9	108
4	Prostate Cancer Cell Lines under Hypoxia Exhibit Greater Stem-Like Properties. PLoS ONE, 2011, 6, e29170.	1.1	88
5	Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU International, 2012, 110, 1721-1728.	1.3	81
6	Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA. Clinical Nutrition, 2017, 36, 672-679.	2.3	65
7	Transperineal prostate biopsy detects significant cancer in patients with elevated prostateâ€specific antigen (PSA) levels and previous negative transrectal biopsies. BJU International, 2012, 110, E69-75.	1.3	58
8	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncology, The, 2021, 22, 1618-1631.	5.1	48
9	Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother. BJU International, 2012, 109, 1366-1374.	1.3	39
10	Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer. Scientific Reports, 2019, 9, 13579.	1.6	38
11	Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry. BJU International, 2010, 105, 805-811.	1.3	35
12	MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features. Oncotarget, 2016, 7, 40297-40313.	0.8	34
13	Regulation of Transcriptional Activity of the Murine CD40 Ligand Promoter in Response to Signals Through TCR and the Costimulatory Molecules CD28 and CD2. Journal of Immunology, 2001, 166, 4578-4585.	0.4	32
14	Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Populationâ€Based Study. Prostate, 2017, 77, 859-865.	1.2	32
15	The prognostic value of reactive stroma on prostate needle biopsy: A populationâ€based study. Prostate, 2015, 75, 662-671.	1.2	29
16	Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines. Tumor Biology, 2012, 33, 967-978.	0.8	28
17	Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer. BJU International, 2012, 109, 1489-1494.	1.3	28
18	Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immuneâ€evasive B7â€H3â€expressing cell population?. International Journal of Urology, 2012, 19, 749-756.	0.5	25

#	Article	IF	CITATIONS
19	Does a surgeon's annual radical prostatectomy volume predict the risk of positive surgical margins and urinary incontinence at one-year follow-up? - Findings from a prospective national study. Scandinavian Journal of Urology, 2013, 47, 92-100.	0.6	25
20	Photodynamic therapy with methyl aminolevulinate for atypia/carcinoma in situ of the penis. Scandinavian Journal of Urology and Nephrology, 2007, 41, 507-510.	1.4	24
21	Regulation of B cell growth and differentiation via CD21 and CD40. European Journal of Immunology, 1996, 26, 2203-2207.	1.6	23
22	Bother problems in prostate cancer patients after curative treatment. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1067-1078.	0.8	22
23	Routine pelvic MRI using phased-array coil for detection of extraprostatic tumour extension: accuracy and clinical significance. European Radiology, 2013, 23, 1158-1166.	2.3	21
24	The relationship between perineural invasion, tumor grade, reactive stroma and prostate cancer-specific mortality: A clinicopathologic study on a population-based cohort. Prostate, 2016, 76, 207-214.	1.2	21
25	The Length of a Positive Surgical Margin Is of Prognostic Significance in Patients with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy. Urologia Internationalis, 2014, 93, 289-295.	0.6	18
26	Diagnosis and treatment of primary signet-ring cell carcinoma of the prostate. Acta Oncol \tilde{A}^3 gica, 2007, 46, 1195-1197.	0.8	16
27	Psychometric properties of the expanded prostate cancer index composite - 26 instrument in a cohort of radical prostatectomy patients: theoretical and practical examinations. BMC Urology, 2017, 17, 111.	0.6	16
28	High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity. Neoplasia, 2021, 23, 634-641.	2.3	16
29	Do Perceptions of Adverse Events Differ Between Patients and Physicians? Findings From a Randomized, Controlled Trial of Radical Treatment for Prostate Cancer. Journal of Urology, 2010, 184, 525-531.	0.2	15
30	Combining lymphovascular invasion with reactive stromal grade predicts prostate cancer mortality. Prostate, 2016, 76, 1088-1094.	1.2	15
31	Sentinel node procedure in low-stage/low-grade penile carcinomas. Scandinavian Journal of Urology and Nephrology, 2006, 40, 204-207.	1.4	13
32	Longâ€term firstâ€inâ€man Phase I/II study of an adjuvant dendritic cell vaccine in patients with highâ€risk prostate cancer after radical prostatectomy. Prostate, 2022, 82, 245-253.	1.2	13
33	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer, 2018, 118, 266-276.	2.9	12
34	Genetic factors influencing prostate cancer risk in Norwegian men. Prostate, 2018, 78, 186-192.	1.2	11
35	Robot-assisted radical prostatectomy of clinical high-risk patients with prostate cancer: A controlled study of operative and short-term postoperative events. Scandinavian Journal of Urology, 2013, 47, 449-455.	0.6	10
36	Penile cancer in Scandinavia: Current practice and future perspectives. Scandinavian Journal of Urology, 2016, 50, 90-92.	0.6	10

#	Article	IF	CITATIONS
37	A comparative study of erectile function and use of erectile aids in high-risk prostate cancer patients after robot-assisted laparoscopic prostatectomy. Scandinavian Journal of Urology, 2015, 49, 433-439.	0.6	9
38	Vitamin D, obesity and leptin in relation to bladder cancer incidence and survival: prospective protocol study. BMJ Open, 2018, 8, e019309.	0.8	9
39	SHBG Is an Important Factor in Stemness Induction of Cells by DHT In Vitro and Associated with Poor Clinical Features of Prostate Carcinomas. PLoS ONE, 2013, 8, e70558.	1.1	8
40	Ability to Reach Orgasm in Patients With Prostate Cancer Treated With Robot-assisted Laparoscopic Prostatectomy. Urology, 2016, 92, 38-43.	0.5	8
41	Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway. Urology, 2017, 110, 140-147.	0.5	8
42	Clinicians' use of guidelines as illustrated by curative treatment of prostate cancer at a comprehensive cancer center. Acta Oncológica, 2011, 50, 408-414.	0.8	7
43	Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones. Prostate, 2012, 72, 668-676.	1.2	7
44	Lifestyle associated factors and risk of urinary bladder cancer: A prospective cohort study from Norway. Cancer Medicine, 2020, 9, 4420-4432.	1.3	7
45	Robot-assisted laparoscopic prostatectomy in a 68-year-old patient with previous heart transplantation and pelvic irradiation. Journal of Robotic Surgery, 2012, 6, 81-83.	1.0	6
46	Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci. JCl Insight, 2022, 7, .	2.3	6
47	Uptake and intracellular transportation of a bacterial surface protein in lymphoid cells. Molecular Microbiology, 2002, 44, 917-934.	1.2	4
48	Blocking mtDNA Replication Upregulates the Expression of Stemness-related Genes in Prostate Cancer Cell Lines. Ultrastructural Pathology, 2013, 37, 258-266.	0.4	4
49	The EPIC-26 domain scores after radical prostatectomy are associated with the personality trait of neuroticism. International Urology and Nephrology, 2021, 53, 691-698.	0.6	4
50	Vitamin D and Vitamin Dâ€binding protein and risk of bladder cancer: A nested caseâ€control study in the Norwegian Janus Serum Bank Cohort. Cancer Medicine, 2021, 10, 4107-4116.	1.3	4
51	A cross-sectional study of current work ability after radical prostatectomy. BMC Urology, 2020, 20, 9.	0.6	4
52	Prediagnostic Serum 25-Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort. Clinical Epidemiology, 2021, Volume 13, 801-811.	1.5	3
53	Expressed prognostic biomarkers for primary prostate cancer independent of multifocality and transcriptome heterogeneity. Cancer Gene Therapy, 2022, 29, 1276-1284.	2.2	3
54	Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis. Marine Drugs, 2022, 20, 228.	2.2	3

#	Article	lF	CITATIONS
55	<i>In situ</i> expression of <scp>ERG</scp> protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis. Molecular Oncology, 2022, 16, 2810-2822.	2.1	3
56	Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: A single-centre experience. Scandinavian Journal of Urology, 2015, 49, 218-223.	0.6	2
57	Addressing erectile dysfunction in prostate cancer survivors after radical prostatectomy. Expert Review of Quality of Life in Cancer Care, 2016, 1, 403-420.	0.6	2
58	Biochemical relapse in very high-risk prostate cancer after radical prostatectomy and DC-vaccine loaded with tumor RNA, hTERT, and survivin Journal of Clinical Oncology, 2020, 38, 324-324.	0.8	1
59	Re: Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer. European Urology, 2022, 81, 431.	0.9	1
60	Prediagnostic Serum-25 Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort: Answer to a Short Comment [Response to Letter]. Clinical Epidemiology, 2021, Volume 13, 1061-1062.	1.5	0
61	A Norwegian perspective on the Swedish national guidelines on prostate cancer for non-metastatic disease. Scandinavian Journal of Urology, 2022, 56, 274-276.	0.6	0